Anzeige
Mehr »
Login
Samstag, 11.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Innocan Pharma News: Unfassbare Studie - LPT-Therapie bewahrt Patient vor dem Tod!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DR0J | ISIN: US3621LQ1099 | Ticker-Symbol: G1H
Tradegate
10.05.24
18:25 Uhr
4,500 Euro
+0,062
+1,40 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
G1 THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
G1 THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,3704,53010.05.
4,3524,52410.05.

Aktuelle News zur G1 THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoWhat's Going On With G1 Therapeutics Stock?10
DoG1 Therapeutics jumps amid takeover speculation15
02.05.Earnings call: G1 Therapeutics reports growth and optimistic outlook7
01.05.G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)53RESEARCH TRIANGLE PARK, N.C., May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable...
► Artikel lesen
01.05.G1 Therapeutics, Inc. - 10-Q, Quarterly Report2
01.05.Evaluating G1 Therapeutics: Insights From 5 Financial Analysts2
01.05.Pepper Bio spices up pipeline with $135M deal for G1 Therapeutics' CDK4/6 inhibitor3
01.05.G1 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary5
01.05.G1 Therapeutics & Pepper Bio Sign Global Licensing Agreement for Lerociclib1
01.05.G1 Therapeutics and Pepper Bio sign license agreement for lerociclib1
01.05.G1 Therapeutics reports mixed Q1 results; reaffirms FY24 outlook3
01.05.G1 Therapeutics, Inc. - 8-K, Current Report1
01.05.G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights72- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated...
► Artikel lesen
01.05.G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib35RESEARCH TRIANGLE PARK, N.C. and BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, and Pepper Bio, the world's first transomics drug...
► Artikel lesen
30.04.G1 Therapeutics Q1 2024 Earnings Preview2
17.04.G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 20241
12.04.Breaking Down G1 Therapeutics: 5 Analysts Share Their Views3
04.04.G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference4
01.04.G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)47RESEARCH TRIANGLE PARK, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable...
► Artikel lesen
22.03.G1 Therapeutics, Inc. - 8-K, Current Report3
Seite:  Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1